EUVIMEDEUVIMED entdecken
Crossref

Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma

Yuma Sakamoto, Takashi Ishida, Ayako Masaki, Takayuki Murase, Eiichi Ohtsuka, Morishige Takeshita, Reiji Muto, Ilseung Choi, Hiromi Iwasaki, Asahi Ito, Shigeru Kusumoto, Nobuaki Nakano und 8 weitere

International Journal of Hematology · 2025

DOI: 10.1007/s12185-024-03880-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, 2025. Verfasst von Yuma Sakamoto und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-86…. Hauptthemen laut MEDLINE: F-Box-WD Repeat-Containing Protein 7, Receptor, Notch1, Leukemia-Lymphoma, Adult T-Cell, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Grants-in-Aid for Early-Career Scientists, Grants-in-Aid for Scientific Research (C), Grant-in-Aid for Challenging Research (Exploratory).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Here, we investigated the clinical significance of NOTCH1 and FBXW7 alterations for adult T-cell leukemia/lymphoma (ATLL) treatment outcomes. NOTCH1 alterations were identified in 37 (14.4%) of 257 patients, of which 33 were single nucleotide variants/insertion-deletions in the PEST domain, and 7 were in the heterodimerization or LIN-12/Notch repeats domains. FBXW7 alterations were observed in nine ATLL patients (3.5%). For patients without allogeneic hematopoietic stem cell transplantation (HSCT), NOTCH1, but not FBXW7, alterations were significantly and independently associated with worse overall survival (median OS 0.5 years, 95% confidence interval [CI] 0.4-0.5 years for 27 patients with NOTCH1 alterations vs 1.8 years, 95% CI 1.3-2.2 years for 170 patients without). Also, for patients receiving mogamulizumab, but not allogeneic-HSCT, NOTCH1, but not FBXW7, alterations were significantly associated with worse survival (median survival from the first dose of mogamulizumab 0.4 years, 95% CI 0.3-0.5 years for 12 patients with NOTCH1 alterations vs 1.4 years, 95% CI 0.9-2.0 years for 87 without). In contrast, NOTCH1 alterations had no significant impact on survival of patients who did receive allogeneic-HSCT. Thus, mogamulizumab-containing treatment was unable to overcome treatment refractoriness of ATLL with NOTCH1 alterations. Therefore, patients with NOTCH1 alterations are recommended for allogeneic-HSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

F-Box-WD Repeat-Containing Protein 7Receptor, Notch1Leukemia-Lymphoma, Adult T-CellMutationHumansMiddle AgedMaleFemaleAdultAgedHematopoietic Stem Cell TransplantationTreatment OutcomeYoung AdultPrognosisClinical Relevance

Stichwörter der Autor:innen

FBXW7NOTCH1Adult T-cell leukemia/lymphomaHematopoietic stem cell transplantationMogamulizumab

Substanzen

F-Box-WD Repeat-Containing Protein 7Receptor, Notch1FBXW7 protein, humanNOTCH1 protein, human

Autor:innen und Institutionen

  • Department of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-8601, Japan. syuma@med.kawasaki-m.ac.jp.
  • Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-Ku, Nagoya, 467-8601, Japan.
  • Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
  • Department of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
  • Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.

Förderung

  • Grants-in-Aid for Early-Career Scientists
  • Grants-in-Aid for Scientific Research (C)
  • Grant-in-Aid for Challenging Research (Exploratory)
  • Grant-in-Aid for Scientific Research (B)
  • Grants-in-Aid from the Japan Agency for Medical Research and Development
  • Nippon Shinyaku Research Grant
  • Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care

Zitieren

APA

Sakamoto, Y., Ishida, T., Masaki, A., Murase, T., Ohtsuka, E., Takeshita, M., Muto, R., Choi, I., Iwasaki, H., Ito, A., Kusumoto, S., Nakano, N., Tokunaga, M., Yonekura, K., Tashiro, Y., Suehiro, Y., Iida, S., Utsunomiya, A., Ueda, R., & Inagaki, H. (2025). Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03880-3

Vancouver

Sakamoto Y, Ishida T, Masaki A, Murase T, Ohtsuka E, Takeshita M, et al. Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma. International Journal of Hematology. 2025. doi:10.1007/s12185-024-03880-3

BibTeX
@article{Sakamoto2025,
  author = {Sakamoto, Yuma and Ishida, Takashi and Masaki, Ayako and Murase, Takayuki and Ohtsuka, Eiichi and Takeshita, Morishige and Muto, Reiji and Choi, Ilseung and Iwasaki, Hiromi and Ito, Asahi and Kusumoto, Shigeru and Nakano, Nobuaki and Tokunaga, Masahito and Yonekura, Kentaro and Tashiro, Yukie and Suehiro, Youko and Iida, Shinsuke and Utsunomiya, Atae and Ueda, Ryuzo and Inagaki, Hiroshi},
  title = {Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma},
  journal = {International Journal of Hematology},
  year = {2025},
  doi = {10.1007/s12185-024-03880-3}
}
Kostenlos starten →